Overview
- The U.S. International Trade Commission closed Masimo’s enforcement case after declining to review an administrative judge’s finding, leaving no import ban on Apple’s redesigned watches.
- An ITC judge ruled in March that Apple’s updated blood‑oxygen setup does not infringe the Masimo patents asserted in the case.
- Apple redesigned the feature so the watch gathers data while a paired iPhone processes and displays the reading, a configuration U.S. Customs previously approved as compliant.
- The original on‑watch version is still barred in the United States because the Federal Circuit upheld the ITC’s 2023 exclusion order.
- Masimo can appeal this ITC decision and is continuing related fights, including a court challenge to the Customs approval and a separate $634 million California verdict that Apple says it will appeal.